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Introduction: Neisseria meningitidis is one of the leading causes of bacterial meningitis. In 2013, an 
increase in invasive disease caused by N. meningitidis serogroup B occurred in Cartagena, Colombia.
Objective: The aim of this study was to characterize serogroup B isolates recovered from patients with 
meningococcal meningitis in Cartagena during 2012 and 2014.
Materials and methods: Twenty-five isolates were collected through a national, laboratory-based 
surveillance, and phenotypic and genotypic characteristics were determined by serosubtyping, 
serotyping, antimicrobial susceptibility testing, repetitive sequence-based PCR (rep-PCR). MLST data 
available were also used.
Results: The B:10,15:nt phenotype, associated with clonal complex ST-41/44, was responsible for 
68.0% of all cases.
Conclusion: The clinical, epidemiological and molecular characterization of meningococcal disease is 
necessary for understanding the spread of virulent meningococcal clones and for facilitating the early 
detection of cases to reduce epidemic risks.
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Caracterización fenotípica y genotípica de aislamientos de Neisseria meningitidis, serogrupo B, 
procedentes de Cartagena, Colombia, 2012-2014
Introducción. Neisseria meningitidis es una de las causas principales de meningitis bacteriana. En el 
2013 se evidenció un aumento de la enfermedad invasiva causada por N. meningitidis, serogrupo B, 
en Cartagena, Colombia.
Objetivo. El objetivo de este estudio fue caracterizar los aislamientos de N. meningitidis, serogrupo B, 
recuperados de pacientes con meningitis meningocócica en Cartagena durante el año 2013.
Materiales y métodos. Se recolectaron 25 aislamientos a través de la vigilancia basada en el laboratorio 
nacional y se determinaron las características fenotípicas y genotípicas mediante serosubtipificación, 
serotipificación, pruebas de sensibilidad a los antimicrobianos, amplificación de secuencias de ADN 
repetidas (REP-PCR) y el uso de datos disponibles en el sitio de MLST.
Resultados. El fenotipo B:10,15:nt, asociado con el complejo clonal ST-41/44, fue responsable del 
68,0 % de todos los casos.
Conclusión. La caracterización clínica, epidemiológica y molecular de los aislamientos causantes de 
enfermedad meningocócica es necesaria para el conocimiento de la propagación de clones virulentos 
y facilita la detección temprana de casos, lo que reduce los riesgos de epidemia.
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Neisseria meningitidis has become the leading 
cause of bacterial meningitis in children, espe-
cially after the introduction of Streptococcus 
pneumoniae and Haemophilus influenzae type b 
routine vaccination (1). There are 12 serogroups of 
N. meningitidis; however, the majority of invasive 
meningococcal infections is caused by serogroups 
A, B, C, W, X and Y, and the distribution varies with 
the geographical location and the age group (2). The 
overall incidence of meningococcal disease differs 
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from one region to another ranging between <2 
cases/100,000 population per year in the United 
States, China and European and Latin American 
countries, and >10/100,000 population per year in 
some African countries (3,4).
N. meningitidis serogroup B has emerged as 
an important cause of invasive meningococcal 
disease in some regions of Europe, Latin America 
and North America since the introduction of 
vaccines against serogroups A and C (5). Despite 
the genetic heterogeneity of serogroup B strains, 
two hypervirulent clonal complexes, ST-41/44 3 and 
ST-32, are responsible for the majority of serogroup 
B disease cases in several countries (5). In 2012, 
33 cases of meningococcal disease were reported 
in Colombia, of which 69.7% were caused by N. 
meningitidis serogroup B (6). In 2012, an increase 
in invasive disease caused by N. meningitidis 
serogroup B (25 cases in total) was observed in 
Cartagena de Indias, Colombia, which has been 
declared by UNESCO as a world heritage site. In 
the present study, we characterized N. meningitidis 
serogroup B isolates recovered between 2012 and 
2014 from infected patients living in deprived urban 
areas in Cartagena.
Materials and methods
We analyzed 25 N. meningitidis isolates recovered 
between March, 2012, and October, 2014, from 
cerebrospinal fluid (CSF) or blood samples of 
meningococcal disease patients. The isolates 
were received at the Colombian Instituto Nacional 
de Salud through the SIREVA II international 
surveillance network (6). We confirmed isolates by 
using standard microbiology techniques, while the 
serogroup was determined by slide agglutination 
with commercial antiserum against meningo-
coccal capsular polysaccharides (DIFCO, Beckton 
Dickinson). Serosubtyping and serotyping were 
done by dot blot with monoclonal antibodies 
(RIVM, Bilthoven, the Netherlands, and Institute 
Adolfo Lutz, São Paulo, Brazil) (7). Agar dilution 
antimicrobial susceptibility testing for penicillin 
(P), ceftriaxone (CRO), chloramphenicol (CL), 
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ciprofloxacin (CIP) and rifampin (RIF) was per-
formed according to the Clinical and Laboratory 
Standards Institute guidelines (8). 
We performed genotyping on the 19 isolates using 
the bacterial rep-PCR-DiversiLab kit (Bacterial 
BarCodes, bioMérieux Inc., Houston, TX) following 
the manufacturer’s recommendations. We analyzed 
patterns by using the Pearson correlation coefficient 
to create a dendrogram of the genetic relationship 
among isolates (9). Clusters of rep-PCR patterns 
exhibiting a similarity of >93% were designated by 
capital letters. Additionally, we included data from 
the Multi Locus Sequence Typing (MLST) site for 
four isolates recovered in 2010 (isolate 858), 2011 
(isolates 903 and 905) and 2012 (isolate 926), 
which were studied as part of a SIREVA II Latin 
American project. MLST was performed according 
to the methods of Maiden, et al. Primers, as well 
as the determination of sequence alleles and the 
designation of sequence types, were retrieved 
from the MLST website (http://neisseria.org/nm/
typing/mlst).
Results
The 25 N. meningitidis serogroup B isolates were 
sent by six hospital laboratories, but 50% of them 
were recovered in only one hospital. All patients 
came from a geographically defined area in 12 of 
the 250 city districts characterized by high levels of 
poverty and low educational levels.
Seventy six per cent of meningococcal disease 
was diagnosed in men; patients’ ages ranged from 
one month to 55 years: 8 isolates (32.0%) were 
recovered from patients <5 years of age; 8 (32.0%), 
from patients 5 to 14 years of age, and 8 (32.0%) 
from patients >14 years of age; no information was 
available for one of the patients (4.0%). Isolates 
were recovered from blood (60.0%) and CSF 
(40.0%) samples. Patients had been diagnosed 
with meningitis (60.0%), meningococcemia (32.0%) 
and bacteremia (8.0%). Two (8.0%) were penicillin-
non-susceptible isolates (0.250 µg/mL), whereas 
all of them were susceptible to CRO, CL, CIP and 
RIF (table 1).
The most prevalent serotype and serosubtype was 
B:10,15:nt (60.0%), followed by B:1:P1.22-1,14 
(16.0%) (figure 1). Isolates were grouped in three 
rec-PCR clusters (A, B, C) designated by size, 
of which A was the largest (figure 1). Cluster A, 
grouping 17 isolates from the study and 2 controls 
(isolates 903 and 905), was B:10,15:nt and showed 
genetic relation with the clonal complex ST-41/44. 
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Table 1. Patient data and microbiological features of N. meningitidis serogroup B isolates collected in Cartagena from 2012 to 2014
Isolate 
code - INS
Date of 
isolation
Patient’s data Antimicrobial susceptibility (MIC)±
Age (years) Gender† Diagnosis P CRO RIF CL CIP
  926
  927
  929
  941
  953
  955
  958
  969
  973
  978
  982
  987
  989
  992
  993
  994
1002
1004
1006
1008
1015
1017
1018
1033
1044
06/03/2012
06/03/2012
14/03/2012
09/07/2012
26/10/2012
30/11/2012
07/12/2012
13/03/2013
23/05/2013
05/06/2013
04/07/2013
16/07/2013
25/09/2013
05/10/2013
11/10/2013
25/10/2013
03/12/2013
12/12/2013
10/01/2014
04/03/2014
16/04/2014
30/04/2014
30/04/2014
01/05/2014
04/10/2014
  5
  1
  2
ND**
54
29
32
  8
  4
  5
  8
  7
  9
9 m*
55
51
  8
14
30
1 m*
4 m*
  4
48
19
  2
F
M
M
F
M
M
M
M
M
M
F
M
M
M
M
M
M
M
M
M
F
F
M
F
M
Meningococcemia
Meningococcemia
Bacteremia
Meningitis
Meningitis
Meningococcemia
Meningitis
Meningococcemia
Meningococcemia
Meningitis
Meningitis
Meningitis
Meningococcemia
Meningitis
Meningitis
Meningitis
Meningococcemia
Meningitis
Meningitis
Meningitis
Meningitis
Meningitis
Meningitis
Bacteremia
Meningococcemia
0.06
  0.125
0.06
0.03
0.06
0.06
0.06
0.25
0.06
0.06
0.25
0.03
0.03
0.03
0.06
0.03
0.25
0.06
0.06
0.06
0.03
  0.016
0.03
  0.125
0.06
0.001
0.001
0.001
0.001
0.001
0.001
  0.0005
0.004
0.001
0.004
0.004
<0.002
0.002
<0.002
<0.002
<0.002
0.001
0.002
0.002
0.002
  0.0005
0.001
0.005
  0.0005
0.001
0.06
0.03
0.06
0.06
0.03
0.06
0.03
<0.016
0.25
  0.125
  0.008
  0.008
  0.004
  0.016
0.06
0.06
0.06
  0.125
0.06
0.03
  0.125
0.03
0.06
  0.016
0.03
1
1
1
1
2
2
2
2
2
2
1
0.5
0.5
1
2
1
2
2
1
2
2
2
2
2
2
0.016
0.016
0.016
0.016
0.004
0.016
0.016
0.016
0.016
0.016
0.002
0.002
0.004
0.008
0.016
0.008
0.016
0.016
0.004
0.016
0.016
0.016
0.016
0.008
0.008
*Months
†M: Male; F: Female
±Minimum Inhibitory Concentration to: P = penicillin, CL = chloramphenicol, CIP = ciprofloxacin, CRO = ceftriaxone, RIF = rifampin
**ND: No data
Three B:1:P1.22-1,14 isolates were grouped as 
cluster B, and five isolates with different serotype 
and serosubtype were grouped in cluster C. Isolate 
858 from 2010 was B:4,7:P1.1 and the clonal 
complex was ST23.
Discussion
Using molecular techniques, we characterized inva-
sive N. meningitidis serogroup B isolates that had 
circulated in Cartagena as part of a meningococcal 
disease epidemic affecting low socioeconomic 
population groups considered at high risk for the 
disease (10). Serogroup B has become a recent 
threat with sporadic, endemic and epidemic occur-
rences being recorded in North America, Europe, 
South America and Australia (5). From 1987 through 
2012, 680 N. meningitidis isolates were confirmed in 
Colombia by the Microbiology Group of the Instituto 
Nacional de Salud, of which 72.2% (n=491) were 
serogroup B (6).
Overall, isolates were susceptible to most of the 
antibiotics tested. SIREVA II data showed that 
between 2006 and 2010, N. meningitidis isolates 
recovered in Bolivia, Colombia, Ecuador, Perú and 
Venezuela corresponded predominantly to sero-
groups B and Y (41.7% and 29.1%, respectively). 
Decreased sensitivity to P was found in 17.1% of 
isolates (16.1% intermediate and 1.0% fully resis-
tant isolates) while all of them remained highly 
susceptible to RIF (99.5%) (11). A systematic 
review of the effectiveness of different antibiotics 
for prophylaxis against meningococcal disease 
found that penicillin and rifampin proved effective 
for eradicating N. meningitidis; however, the use 
of rifampin may lead to the emergence of resistant 
strains (12). Therefore, antimicrobial chemopro-
phylaxis for close contacts of patients with invasive 
meningococcal disease could be important to 
prevent further cases (12).
The information on the distribution of N. meningitidis 
serogroup B isolates serosubtypes and serotypes is 
important in evaluating the possibility of using outer 
membrane protein (OMP) based vaccines to control 
endemic meningococcal disease (13). However, 
the variability in OMP strains causing endemic dis-
ease will likely limit their usefulness (10). The main 
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Figure 1. Similarity dendrogram showing the relatedness of rep-PCR profiles and MLST of N. meningitidis serogroup B isolates 
collected in Cartagena from 2012 to 2014
serosubtype and serotype (B:10,15:nt) identified in 
this study differ from those in the vaccines currently 
licensed: The Cuban VA-MENGOC-BC vaccine, 
which was developed from the outer membrane 
antigens of the epidemic strain type B:4:P1.15 
combined with serogroup C polysaccharide (14), 
and a multicomponent serogroup B meningococcal 
vaccine (4CMenB), consisting of factor-H binding 
protein (fHbp), N. meningitidis adhesin A (NadA) 
and Neisseria heparin binding antigen (NHBA), 
Isolate MLST Sero/subtype Pattern Electrophoretic pattern
Nm 955 B:10,15:nt
B:10,15:nt
B:10,15:nt
B:10,15:nt
B:10,15:nt
B:10,15:nt
B:10,15:nt
B:10,15:nt
B:10,15:nt
B:10,15:nt
B:10,15:nt
B:4.7:P1.15
B:10:nt
B:10,15:nt
B:10,15:nt
B:1:P1.22-1,14
B:1:P1.22-1,14
B:4,7:P1.22-1
B:1:P1.22-1
B:1,10:P1.22-1
B:4,7:nt
B:4,7:P1.22-1
B:4,7:P1.1
B:7:nt
B:10,15:nt
B:10,15:nt
B:10:nt
B:10:nt
Nm 958
ST-41/44
ST-41/44
ST-41/44
ST-23
Nm 978
Nm 1044
Nm 993
Nm 905
Nm 989
Nm 903
Nm 1033
Nm 926
Nm 927
Nm 929
Nm 987
Nm 1015
Nm 1017
Nm 1018
Nm 1006
Nm 973
Nm 994
Nm 969
Nm 1008
Nm 982
Nm 1004
Nm 1002
Nm 941
Nm 953
Nm 992
Nm 858
% Similarity
65 70 75 80 85 90 95 100
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
A
B
B
B
C
C
C
C
C
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combined with outer membrane vesicles from 
the New Zealand epidemic strain NZ98/254 
(B:4:P1.7b,4) (15). This vaccine was approved 
for use in the European Union and Australia, and 
has been found to be safe and immunogenic in a 
Latin American adolescent population (10,16). The 
predicted protection of this new vaccine is dependent 
of vaccine antigens expressed by strains causing 
disease in different geographical settings, therefore, 
fHbp, NadA and NHBA genetic typing of invasive N. 
meningitidis serogroup B isolates is required.
A limited number of clonal complexes are respon-
sible for the majority of the disease cases asso-
ciated with outbreaks or epidemics. In our study, 
the most common clonal complex was ST-41/44, 
found in 64.3% of cases. The ST-41/44 is the 
most diverse clonal complex associated with 
serogroup B meningococcal disease, and the 
analysis of available MLST data showed that the 
most common serotypes in this complex are 41, 
44, 42, 40 and 154 (5). This clonal complex has 
caused epidemics in the Netherlands and New 
Zealand and was the dominant cause of invasive 
meningococcal disease in Ireland, Belgium and 
Italy (5). In Chile, the ST-41/44 complex, mostly 
associated with B:P1.19,13-1, showed the highest 
prevalence (29.0%), (17), while in Argentina, only 
7% of the serogroup B isolates in 2010 belonged to 
the ST-41/44 complex (18).
Phenotyping and genotyping methods are impor-
tant for meningococcal transmission studies and 
epidemics early detection. Additionally, molecular 
surveillance is crucial to identify genotypes indi-
cating disease common sources, as well as to 
determine the antigenic profile and clonal diversity 
of N. meningitidis isolates associated with inva-
sive disease, and to monitor the evolution and 
distribution of meningococcal serogroups and 
clones in order to provide information for future 
vaccine development.
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